STOCK TITAN

Veru - VERU STOCK NEWS

Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.

Veru Inc. (NASDAQ: VERU) is a late clinical-stage biopharmaceutical company advancing innovative therapies for cardiometabolic diseases, oncology, acute respiratory distress syndrome (ARDS), and sexual health. This page provides investors and stakeholders with timely updates on clinical trial progress, regulatory milestones, and strategic initiatives.

Access the latest Veru news, including press releases on drug development programs like enobosarm for muscle preservation during weight loss and sabizabulin for inflammatory conditions. Stay informed about earnings updates, partnership announcements, and scientific advancements across Veru's diversified pipeline.

All content is sourced directly from company communications and vetted financial news outlets. Bookmark this page for streamlined access to critical updates affecting Veru investment analysis and market positioning.

Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) will release its fiscal 2021 first quarter financial results on February 10, 2021, before market opening. A conference call will be held at 8 a.m. ET on the same day to discuss the company’s performance and answer questions. Veru focuses on oncology, developing treatments for prostate and breast cancer, including clinical trials for its drug candidates VERU-111 and VERU-100. The company is also advancing multiple clinical trials across its pipeline and will provide insights into future developments during the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
conferences earnings
-
Rhea-AI Summary

Veru Inc. announced a significant breakthrough in breast cancer research, revealing the androgen receptor acts as a tumor suppressor in ER+ breast cancer. Preclinical studies indicate that enobosarm, a selective androgen receptor agonist, shows potent antitumor activity in resistant cases. The Phase 3 ARTEST study for enobosarm is set to commence next quarter, targeting patients resistant to existing therapies. This research could change treatment approaches and emphasizes enobosarm's potential without unwanted side effects, marking a new era in breast cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
none
-
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) announced its participation in the H.C. Wainwright Bioconnect 2021 Conference, with an on-demand presentation available from January 11-14, 2021. The webcast will also be archived for 90 days. Veru focuses on oncology, developing treatments for prostate and breast cancer, including investigational drugs such as VERU-111, VERU-100, and enobosarm. The company plans to advance various clinical trials throughout 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.94%
Tags
conferences
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) announced promising results from its Phase 2 clinical trial for enobosarm, focused on ER+/HER2- metastatic breast cancer. Highlighted as a Spotlight Presentation at the 2020 San Antonio Breast Cancer Symposium, enobosarm showed a clinical benefit rate of 32% in a 136-patient cohort. The FDA has approved a Phase 3 ARTEST study, set to begin in Q2 2021, to further evaluate enobosarm's efficacy against active comparators in similar patient populations. This novel therapy offers hope for patients who have exhausted other treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
52.52%
Tags
-
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) presented promising preclinical data for VERU-111, showing its potential in treating triple negative breast cancer (TNBC) resistant to paclitaxel. Findings from the 2020 San Antonio Breast Cancer Symposium revealed that VERU-111 significantly inhibited tumor growth in both paclitaxel-sensitive and resistant models. The company plans to engage with the FDA in early 2021 to discuss advancing VERU-111 into a Phase 2b clinical trial for women with taxane-resistant TNBC, potentially leading to accelerated approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
52.52%
Tags
none
-
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) has completed its transformation into a late-stage oncology biopharmaceutical company focused on prostate and breast cancer therapies. It has licensed worldwide rights to enobosarm, an oral androgen receptor targeting agent for endocrine-resistant ER+ HER2- metastatic breast cancer. Veru plans to initiate four registration trials in 2021, including the ARTEST trial for enobosarm and studies for VERU-111 and VERU-100. The company expects to fund these trials through existing resources without the need for new equity financing until at least FY 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.69%
Tags
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) reported record financial results for fiscal 2020, with net revenues rising 34% to $42.6 million and gross profit increasing 42% to $30.8 million. Notably, FC2 prescription sales surged 93% to $27.1 million. Despite a net loss of $19 million, which included a $14.1 million non-cash impairment charge, adjusted operating loss improved significantly. The company completed the $20 million sale of its PREBOOST business and anticipates that current cash and operational cash flow will support drug development through at least fiscal 2022. Key clinical trials are advancing, including a late-stage breast cancer drug entering Phase 3.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.69%
Tags
-
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) will report its fiscal 2020 fourth quarter and year results on December 9, 2020, before the market opens. Management will host a conference call at 8 a.m. ET to discuss performance and answer questions. Veru focuses on developing novel medicines for prostate cancer, including VERU-111 and VERU-100. The company is advancing multiple clinical studies and expects to begin a Phase 2 trial for VERU-100 in Q1 2021 and submit the NDA for TADFYN® early next year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
conferences earnings
-
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) announced its participation in four upcoming healthcare investor conferences, aimed at discussing its innovative biopharmaceutical solutions for prostate cancer management. The conferences include the Morgan Stanley Virtual Healthcare Conference from September 14-18, 2020, and the Cantor Fitzgerald Global Healthcare Conference on September 15-17, where Veru will present on September 15 at 8:00 a.m. ET. Additionally, the company will present at the H.C. Wainwright Conference on September 16 and the Oppenheimer Summit on September 21, with a focus on its pipeline products, including VERU-111 and VERU-100.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
conferences
Rhea-AI Summary

Veru Inc. (NASDAQ: VERU) has signed a three-year multi-million unit extension agreement with Roman, a leader in men's digital health, for the exclusive U.S. distribution of its PREBOOST® (4% benzocaine wipes) under the Roman Swipes brand. The partnership aims to increase patient access to this product for the treatment of premature ejaculation (PE), which affects 20-30% of men. Mitchel Steiner, CEO, emphasized the importance of this collaboration in providing convenient, clinically-backed treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
Veru

Nasdaq:VERU

VERU Rankings

VERU Stock Data

78.20M
119.10M
14.21%
40.08%
9.36%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI